

## DESCRIPTION

<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human IL-33 in direct ELISAs.
<b>Source</b>	Recombinant Monoclonal Goat IgG Clone # 40015C
<b>Purification</b>	Protein A or G purified from cell culture supernatant
<b>Immunogen</b>	<i>E.coli</i> -derived recombinant human IL-33 Ser112-Thr270 Accession # O95760
<b>Conjugate</b>	Phycoerythrin Excitation Wavelength: 488 nm Emission Wavelength: 565-605 nm
<b>Formulation</b>	Supplied in a saline solution containing BSA and Sodium Azide. See Certificate of Analysis for details.  *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.


## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

	Recommended Concentration	Sample
<b>Intracellular Staining by Flow Cytometry</b>	10 $\mu$ L/10 <sup>6</sup> cells	See Below


## DATA

**Intracellular Staining by Flow Cytometry**



**Detection of IL-33 in Human Peripheral Blood Lymphocytes by Flow Cytometry.** Human peripheral blood lymphocytes were stained with (A) Goat Anti-Human IL-33 PE-conjugated Monoclonal Antibody (Catalog # IC36253P) or (B) Goat IgG PE-conjugated control antibody (Catalog # IC108P) and Mouse anti-Human CD19 APC-conjugated Monoclonal Antibody (Catalog # FAB4867A). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with methanol.

**Intracellular Staining by Flow Cytometry**



**Detection of IL-33 in HUVECs by Flow Cytometry.** HUVECs were stained with Goat Anti-Human IL-33 PE-conjugated Monoclonal Antibody (Catalog # IC36253P, filled histogram) or Goat IgG PE-conjugated control antibody (Catalog # IC108P, open histogram). To facilitate intracellular staining, cells were fixed with Flow Cytometry Fixation Buffer (Catalog # FC004) and permeabilized with methanol.

## PREPARATION AND STORAGE

<b>Shipping</b>	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<b>Protect from light. Do not freeze.</b> <ul style="list-style-type: none"> <li>12 months from date of receipt, 2 to 8 °C as supplied.</li> </ul>

## BACKGROUND

IL-33, also known as NF-HEV and DVS 27, is a 30 kDa proinflammatory protein that may also regulate gene transcription (1-3). DVS 27 was identified as a gene that is up-regulated in vasospastic cerebral arteries (1). NF-HEV was described as a nuclear factor that is preferentially expressed in the endothelial cells of high endothelial venules relative to endothelial cells from other tissues (2). IL-33 was identified based on sequence and structural homology with IL-1 family cytokines (3). DVS 27, NF-HEV, and IL-33 share 100% amino acid sequence identity. IL-33 is constitutively expressed in smooth muscle and airway epithelia. It is up-regulated in arterial smooth muscle, dermal fibroblasts, and keratinocytes following IL-1 $\alpha$  or IL-1 $\beta$  stimulation (1, 3). Similar to IL-1, IL-33 can be cleaved *in vitro* by caspase-1, generating an N-terminal fragment that is slightly shorter than the C-terminal fragment (3, 4). The N-terminal portion of full length IL-33 contains a predicted bipartite nuclear localization sequence and a homeodomain-like helix-turn-helix DNA binding domain. By immunofluorescence, full length IL-33 localizes to the nucleus in HUVECs and transfectants (2). The C-terminal fragment, corresponding to mature IL-33, binds and triggers signaling through mast cell IL-1 R4/ST2L, a longtime orphan receptor involved in the augmentation of Th2 cell responses (3, 5-7). A ternary signaling complex is formed by the subsequent association of IL-33 and ST2L with IL-1R AcP (8). Stimulation of Th2 polarized lymphocytes with mature IL-33 *in vitro* induces IL-5 and IL-13 secretion (3). *In vivo* administration of mature IL-33 promotes increased production of IL-5, IL-13, IgE, and IgA, as well as splenomegaly and inflammatory infiltration of mucosal tissues (3). Full length and mature human IL-33 share 52-58% aa sequence identity with mouse and rat IL-33. Human IL-33 shares less than 20% aa sequence identity with other IL-1 family proteins.

## References:

1. Onda, H. *et al.* (1999) *J. Cereb. Blood Flow Metab.* **19**:1279.
2. Baekkevold, E.S. *et al.* (2003) *Am. J. Pathol.* **163**:69.
3. Schmitz, J. *et al.* (2005) *Immunity* **23**:479.
4. Black, R.A. *et al.* (1989) *J. Biol. Chem.* **264**:5323.
5. Xu, D. *et al.* (1998) *J. Exp. Med.* **187**:787.
6. Lohning, M. *et al.* (1998) *Proc. Natl. Acad. Sci. USA* **95**:6930.
7. Dinarello, C.A. (2005) *Immunity* **23**:461.
8. Chackerian, A.A. *et al.* (2007) *J. Immunol.* **179**:2551.